Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* For Episodic Migraine participants: Participants who completed the treatment period of Galcanezumab study CGAN.~* Have a diagnosis of chronic migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.3) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to screening, and migraine onset prior to age 50.~Exclusion Criteria:~* For Chronic Migraine participants:~  * Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.~ * Current use or prior exposure to Galcanezumab or other antibodies of calcitonin gene-related peptide (CGRP) or its receptor.~ * Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to Galcanezumab and the excipients in the investigational product.~ * History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.~ * Failure to respond to 3 or more adequately dosed migraine preventive treatments from different classes (that is, maximum tolerated dose for at least 2 months).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 120mg/120mg Galcanezumab - Episodic Migraine (EM) (Type: EXPERIMENTAL): 240 milligram (loading dose) of Galcanezumab at first dosing visit followed by 120 milligram (mg) once a month for a year by subcutaneous (SC) injection. EM participants (pts) rolled over from CGAN (NCT02959177) 120 mg Galcanezumab.
- 240mg/240mg Galcanezumab - EM (Type: EXPERIMENTAL): 240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) 240 mg Galcanezumab.
- Placebo/ 120mg Galcanezumab - EM (Type: EXPERIMENTAL): 240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. EM participants rolled over from CGAN (NCT02959177) placebo.
- Placebo/ 240mg Galcanezumab - EM (Type: EXPERIMENTAL): 240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) Placebo.
- 120mg Galcanezumab - CM (Type: EXPERIMENTAL): 240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. Participants with CM were enrolled.
- 240mg Galcanezumab - CM (Type: EXPERIMENTAL): 240 mg Galcanezumab given SC once a month for a year. Participants with CM were enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete